ARTICLE | Company News
Amgen sales and marketing update
March 21, 2016 7:00 AM UTC
The U.K.’s NICE issued draft guidance recommending against the use of Imlygic talimogene laherparepvec to treat unresectable melanoma that is regionally or distantly metastatic with no bone, brain, l...